Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer

Cancer Gene Therapy

Volumn 9, Issue 7, 2002, Pages 613-623

  Lamers, Cor H J ^a   Willemsen, Ralph A ^a   Luider, Barbara A ^a   Debets, Reno ^a   Bolhuis, Reinder L H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical protocol; Human T lymphocytes; Immunogene therapy; Renal cell carcinoma; Single chain chimeric receptor

Indexed keywords

MONOCLONAL ANTIBODY CD3; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; CANCER; CLINICAL PROTOCOL; CONTROLLED STUDY; GENE THERAPY; GENETIC TRANSDUCTION; GOOD CLINICAL PRACTICE; HUMAN; HUMAN CELL; IMMUNOGENETICS; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENE; CELL CULTURE; CELL DIVISION; CULTURE MEDIUM; CYTOLOGY; FLOW CYTOMETRY; GENE TRANSFER; GENETICS; IMMUNOTHERAPY; KIDNEY TUMOR; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; NEOPLASM; RETROVIRUS; SPECTROFLUOROMETRY; TIME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD4; CARCINOMA, RENAL CELL; CELL DIVISION; CULTURE MEDIA, SERUM-FREE; FLOW CYTOMETRY; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMAN; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LEUKOCYTES, MONONUCLEAR; NEOPLASMS; RETROVIRIDAE; SPECTROMETRY, FLUORESCENCE; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES; TUMOR CELLS, CULTURED; HUMANS;

EID: 0036019378     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700477     Document Type: Article

References (43)

1. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
2. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes
3. The use of hybrid hybridomas to target human cytotoxic T lymphocytes
4. Induction of tumour cell lysis by bi-specific monoclonal antibodies recognizing renal cell carcinoma and CD3 antigen
5. Human T lymphocytes targeted against an established human ovarian carcinoma with a bi-specific F(ab′)2 antibody prolong host survival in a murine xenograft model
6. Adoptive immunotherapy of ovarian carcinoma with Bs-Mab-targeted lymphocytes: A multi-center study
7. Cure of xenografted human tumours by bi-specific antibodies and human T cells
8. Regression of advanced ovarian carcinoma by intra-peritoneal treatment with autologous T lymphocytes retargeted by a bi-specific monoclonal antibody
9. Delivery of novel therapeutic agents in tumours: Physiological barriers and strategies
10. Clustered CD3/TCR complexes do not transduce activation signals following bi-specific monoclonal antibody triggered lysis by CTL via CD3
11. Inhibition of bi-specific monoclonal antibody (bs-Ab)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated lymphocytes
12. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the g or z subunits of the immunoglobulin and T-cell receptors
13. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain
14. + T lymphocytes armed with universal T-cell receptors
15. Hormonal therapy and chemotherapy of renal-cell carcinoma
16. High-dose regimen of interleukin-2 (IL2) and interferon-alpha (IFNα) in combination with lymphokine-activated killer cells (LAK) in patients with metastatic renal cell cancer
17. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney
18. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma
19. Targeting of renal cell carcinoma with Iodine-131-labeled chimeric monoclonal antibody G250
20. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated dose radioimmunotherapy
21. Single chain Ig/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity
22. A retroviral vector system "Stitch" in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient transduction and expression in human T lymphocytes
23. Chimeric scFv/gamma receptor-mediated T cell lysis of tumor cells is co-regulated by adhesion and accessory molecules
24. Functional balance between T cell chimeric receptor density and tumor-associated antigen density: CTL mediated cytolysis and lymphokine production
25. Construction and properties of retrovirus packaging cells based on Gibbon Ape Leukemia Virus
26. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bi-specific antibody-directed cellular immunotherapy
27. Exogenous IL-2 recruits in vitro LAK activity by in vivo activated lymphocytes
28. High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments
29. Co-localization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells
30. Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy
31. lck in T-cells infiltrating human renal cell carcinoma
32. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes
33. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression
34. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen
35. Anti-tumor activity of human T cells expressing the CC49-ζ chimeric immune receptor
36. Efficient transfer of a tumor-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity
37. Genetic programming of primary human T lymphocytes with cancer specific chimeric single chain and two chain TCR
38. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes
39. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer
40. High-efficiency retroviral-mediated gene transfer into human and non-human primate peripheral blood lymphocytes
41. Regulation of expression and binding of three VLA (β1) integrin receptors on T cells
42. Co-stimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus
43. T cells activated in vitro as immunotherapy for renal cell carcinoma: Characterization of 2 effector T-cell populations